Full-Time

Senior Manager Regulatory Affairs CMC Combination Product and Stand Alone Medical Device Specialist

Posted on 8/21/2026

Deadline 9/3/26
CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA + 1 more

More locations: Waltham, MA, USA

Remote

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to CSL

See people who can refer or advise you

Requirements
  • A bachelor's degree in an engineering or scientific discipline, or a related field is required.
  • Over 5 years of progressive experience in regulatory roles within the medical device, pharmaceutical, or biotechnological industry, demonstrating increasing levels of responsibility.
  • Extensive experience in the global regulatory device environment, with proven expertise in global pharmaceutical and biotechnological drug development.
  • In-depth knowledge of global device regulatory requirements, including EU MDR, ISO 13485, ISO 14971, ISO 15223, ISO 10993, IEC 62366, IEC 62304, IEC 60601, ISO 20916, ISO 18113, ISO 23640, 21 CFR Part 820, QSR, and BIMO compliance.
  • Demonstrated ability to generate successful FDA, EU, and international submissions, including 513(g) requests, pre-submissions, IDEs, 510(k)s, PMAs, De Novo 510(k)s, and EU MDR product registrations.
  • Experience authoring, reviewing, and managing regulatory submissions, ensuring accuracy, compliance, and timely delivery.
  • Experience managing FDA and notified body interactions, including formal meetings, audits, and inspections.
  • Demonstrated leadership in managing and developing high-performing teams of regulatory device professionals.
  • Ability to support regional and local Regulatory Affairs teams in interactions with health authorities such as EMA, PEI, AGES, PMDA, and Health Canada.
  • Proven capability to develop and implement global device regulatory strategies, resolve complex regulatory challenges, and negotiate optimal pathways and outcomes with health authorities.
  • Ability to motivate, mentor, and guide diverse teams within a matrixed organizational structure.
  • Ability to negotiate, influence, and represent regulatory positions effectively.
  • Ability to use precedent and previous experience to develop innovative and flexible approaches to achieve goals.
Responsibilities
  • Partner closely with R&D, Manufacturing, Operations, Quality, and Regulatory Affairs stakeholders to address regulatory strategy challenges and deliver timely regulatory solutions for plasmapheresis devices, drug-device combination products, standalone drug delivery devices, and ancillary devices.
  • Ensure worldwide regulatory device compliance and successful market access across all regions.
  • Collaborate with internal stakeholders on regulatory strategy issues and develop approaches to address regulatory and compliance matters.
  • Serve as the primary liaison to the US FDA for device matters and work with regional regulatory staff to engage with international health authorities.
  • Represent CSL in official device regulatory capacities and act as an authorized official or responsible person in interactions with regulatory agencies.
  • Promote cross-functional collaboration and communication across Global Operations, R&D, Global Regulatory Affairs, and other relevant CSL business functions.
  • Support implementation of regulatory strategies, objectives, and policies for the Global Regulatory Affairs Device function.
  • Define and optimize regulatory strategies, objectives, and policies governing the development, registration, commercialization, and life-cycle management of CSL's global device portfolio.
  • Collaborate with Global Regulatory Affairs CMC, Global Regulatory Affairs, R&D, Quality, Global Operations, and other business functions to execute activities within global regulatory device strategies.
  • Directly liaise and negotiate with the US FDA and oversee and advise regional regulatory staff on discussions with international health authorities during development and commercial use.
  • Maintain relationships with regulators and ensure timely responses to inquiries and requests.
  • Facilitate timely decision-making and guidance from health authorities through effective communication and relationship management.
  • Author and review regulatory documents, including 510(k), De Novo, PMA, CE mark technical documentation, initial BLA and MAA, international device registrations, post-approval variations and supplements, INDs, CTAs, DHFs, Q-submissions, MAFs, meeting requests, and briefing packages.
  • Ensure accurate and timely change control assessments in CSL's quality management system for device-related change controls, including country-specific reporting categories and submission documentation requirements.
  • Advise on regulatory device strategies, solutions to engineering problems, and interpretation of results in the context of device registration requirements.
  • Support global program planning and regulatory device strategy discussions with CSL stakeholders.
  • Facilitate communication and flow of regulatory information, including regulatory frameworks, scope, and project timelines, to relevant stakeholders.
  • Perform device regulatory assessments during due diligence for acquisitions, licensing, and partnerships.
  • Leverage external insights to refine strategies and implement innovative regulatory approaches for CSL's product portfolio.
  • Provide regulatory consultation to Plasma Operations, Global Operations, R&D, and IT to support compliant business processes and operational excellence.
  • Ensure regulatory policies and procedures are developed and implemented in accordance with applicable international standards and requirements.
  • Support creation and execution of regulatory policies, processes, and standard operating procedures meeting global regulatory requirements while improving operational efficiency across Plasma Operations, Global Operations, R&D, and stakeholders.
  • Support outsourcing of regulatory activities, including submission quality assurance, to ensure timely and compliant service delivery.
Desired Qualifications
  • An advanced degree, such as a Master of Science or Doctor of Philosophy, is preferred.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...